A prospective study of 56 colorectal cancer patients reveals that preoperative circulating tumor DNA (meth-ctDNA) serves as a significant biomarker for assessing treatment plans. Negative preoperative meth-ctDNA correlates with longer median progression-free survival (PFS), identified as a strong independent predictor (HR=3.3). Similarly, negative postoperative meth-ctDNA also indicates improved survival outcomes. This study suggests that assessing meth-ctDNA can inform multidisciplinary decisions regarding the timing and nature of liver interventions and chemotherapy for colorectal liver metastases.
Journal Article by Raunkilde L, Andersen RF (…) Jensen LH et 2 al. in Eur J Surg Oncol
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.